New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2012
16:18 EDTKO, GS, JNJ, SRSL, DTSI, FSLR, AMTG, WHROn The Fly: Closing Wrap
Stocks on Wall Street were significantly higher, as a trio of earnings reports and a boost in the IMF's view of global growth prospects powered the market's rise. Stock futures were higher in pre-market trading on the strength of positive earnings reports from Coca-Cola (KO), Goldman Sachs (GS), and Johnson & Johnson (JNJ). The domestic economic data, which included fewer than expected housing starts and no increase in industrial production, was overshadowed by increased global and U.S. growth forecasts by the International Monetary Fund. With the earnings season beginning in earnest this week, investors appeared bullish about the prospects for solid numbers this quarter, if today's trading is taken as an indication... ECONOMIC EVENTS: In the U.S., housing starts for the month of March decreased 5.8%, versus expectations of an increase of 1%, but the number of building permits issued rose 4.5%, versus expectations of a decrease of 0.7%. Industrial production was reportedly flat in March, versus expectations for a 0.3% increase. Capacity utilization was in line with forecasts at 78.6%. In Europe, a German investor confidence survey was better than expected and Spanish benchmark yields eased back below 6%. Also, the International Monetary Fund said it sees world output growing 3.5% in 2012, raising its projection for United States growth to 2.1%. The IMF also said it sees growth in China slowing to 8.2% and real GDP in the euro area contracting in the first half of 2012 but then recovering... COMPANY NEWS: Coca Cola and Goldman Sachs both reported earnings and revenue that beat the Street's expectations, though Coke saw more of a favorable reaction from investors. Coca Cola shares rose 2.08% to $73.95 after its report, while Goldman fell 0.74% to $116.86. Johnson and Johnson also beat consensus for adjusted earnings, but its revenue came in below forecasts. Shares rose 0.38% to $64.22, making it one of the Dow's laggards during a session that saw all 30 stocks in the index post gains... MAJOR MOVERS: Among the notable gainers were SRS Labs (SRSL), up $2.53, or 36.88%, to $9.39, after agreeing to be acquired by DTS, Inc. (DTSI) in a cash-and-stock transaction valued at $9.50 per share, and First Solar (FSLR), up $2.14, or 10.28%, to $22.96, following its announcement of plans to cut its global workforce by approximately 2,000 positions, or about 30%, in response to conditions in Europe. Noteworthy losers included Apollo Residential Mortgage (AMTG), down $1.37, or 7.16%, to $17.76, after filing to sell 13.9M shares of its common stock, and Whirlpool (WHR), down $3.03, or 4.27%, to $68.00, after the International Trade Commission voted against imposing duties on refrigerators produced in South Korea and Mexico... INDICES: The Dow gained 194.13, or 1.50%, to 13,115.54; the Nasdaq rose 54.42, or 1.82%, to 3,042.82; and the S&P 500 added 21.21, or 1.55%, to 1,390.78.
News For KO;GS;JNJ;SRSL;DTSI;FSLR;AMTG;WHR From The Last 14 Days
Check below for free stories on KO;GS;JNJ;SRSL;DTSI;FSLR;AMTG;WHR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 24, 2014
21:23 EDTGSLender group set to offer EDMC revised debt package, NY Post says
Subscribe for More Information
16:56 EDTGSGoldman likely to limit partner designations this fall, WSJ says
Subscribe for More Information
August 22, 2014
17:18 EDTGSGoldman Sachs announces agreements with FHFA to repurchase $3.15B in RMBS
Subscribe for More Information
13:41 EDTGSGoldman Sachs near $1.1B payment to settle FHFA claims, FT reports
Subscribe for More Information
06:42 EDTGSBlackstone in discussions to back China-based fund, Bloomberg says
Blackstone (BX) is in discussions to possibly back Hong Kong-based distressed fund, Arkkan Capital Management, which was founded by the former global leader of Goldman Sachs' (GS) special situations division Jason Brown, according to Bloomberg, citing two people with knowledge of the matter. Reference Link
August 21, 2014
10:14 EDTDTSIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:43 EDTDTSIDTS, Inc. management to meet with B. Riley
Subscribe for More Information
08:08 EDTDTSIDTS, Inc. upgraded to Outperform from Market Perform at Barrington
Subscribe for More Information
07:50 EDTWHRMajor appliance demand decelerating, says Longbowx
Longbow's North American industry checks indicate major applicance demand had declerated form June/July promotional peaks, indicating a rapid deceleration in the Core 6 category. The firm said the Core 6 categoreis are trending into negative territory following strong July 4th sales event volumes and is hearing laundry sales are particularly weak, and may be by as much as negative double digits. The analyst notes Whirlpool (WHR) is leveraged to laundry sales and, to a lesser extent, AB Electrolux (ELUX).
06:43 EDTGSRegulators up bank warning efforts for poor risk assessment, Reuters says
Subscribe for More Information
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
18:29 EDTGSBofA, JPMorgan weigh plans to raise salaries for junior bankers, Bloomberg says
Subscribe for More Information
11:37 EDTGSGoldman ups U.S. junior employees FY15 wages by 20%, Bloomberg says
Subscribe for More Information
10:32 EDTGSGoldman to up U.S. junior employees FY15 salaries by 20%, Bloomberg says
Subscribe for More Information
August 19, 2014
06:34 EDTGSGoldman abandons effort to toss out $1B Gaddafi suit, Telegraph says
Goldman Sachs (GS) abandoned its effort to toss out a London court suit from the Libyan Investment Authority who alleged that the bank lost over $1B worth of funds during the final years of Muammar Gaddafi's reign as dictator, according to the Telegraph, citing comments from the LIA. The LIA sued both Goldman and Societe Generale (SCGLY) over claims that the banks' London divisions took-in exorbitant fees while losing money in derivative trades. Reference Link
August 18, 2014
13:12 EDTKOAnalysts mixed on Monster Beverage following Coke deal
Analysts had mixed outlooks on energy drink maker Monster Beverage (MNST) in notes to investors earlier today. The analyst comments come after last Thursday night’s announcement that Monster had formed a strategic partnership with Coca-Cola, which included Coca-Cola taking a 16.7% stake in the energy drink maker. BEARISH TAKE: Jefferies analyst Kevin Grundy downgraded Monster Beverage to Hold from Buy, saying that the stock's valuation "looks full" following its rally on Friday. The potential for a strategic deal is no longer a positive catalyst for Monster's stock, as that catalyst largely played out Friday, Grundy believes. Although Coca-Cola is likely to increase its stake in Monster, it will likely take years to do so, the analyst forecast. Additionally, the growth of the global energy drink space has been slowing in recent months, creating risk for Monster, the analyst believes. However, Grundy did raise his price target on the shares to $95 from $80. BULLISH TAKE: The deal is "a big win" for both Monster and Coca-Cola, but Monster will benefit more, analysts at Wells Fargo contended. The deal should significantly increase Monster's opportunity in international markets, according to the firm. Moreover, Wells believes that the market has historically undervalued Monster's international potential, and it estimates that the company's international business is worth about $65 per share. The firm raised its price target range on the stock to $104-$106 from $79-$81 and kept an Outperform rating on the shares. Like Wells Fargo, Credit Suisse expects the deal to accelerate the growth of Monster's international business. Additionally, the firm thinks that Monster could return a significant percentage of the $2.1B it received from Coca-Cola to shareholders, either through share repurchases or a one-time dividend. Credit Suisse increased its price target on Coca-Cola to $98 from $82 and kept an Outperform rating on the shares. PRICE ACTION: In early afternoon trading, Monster dropped 4% to $89.50. On Thursday the stock closed at $71.65.
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
10:32 EDTGSProcter & Gamble likely to divest Duracell, Braun, Reuters reports
Subscribe for More Information
09:20 EDTGSDeutsche Bank appoints Shannon Americas Chief Information Officer
Subscribe for More Information
07:41 EDTKOMonster Beverage price target raised to $104-$106 from $79-$81 at Wells Fargo
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use